<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2019</year>
    <pub-dates>
     <date>2020-10-27</date>
    </pub-dates>
   </dates>
   <doi>10.1002/eji.201970300</doi>
   <abstract>TAMs (tumor-associated macrophages) are innate immune cells, which are present in prostate cancer (PC) tissue.&#13;
TAMs play major role in tumor progression, invasion, neoangiogenesis, metastasis and resistance to therapy. Prostate&#13;
cancer patients often have long time periods between curative intent surgery or radiation therapy until the time of&#13;
biochemical recurrence or metastatic relapse is detectable but the disease at this stage can be incurable with the&#13;
current treatment options. We believe that correctly identifying the phenotype of TAMs and the corresponding&#13;
molecular biomarkers can predict the aggressiveness of PC, response to chemotherapy and development of&#13;
postoperative metastasis.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/923</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/1047</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
